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Trends in future health financing and coverage: future health 
spending and universal health coverage in 188 countries, 
2016–40
Global Burden of Disease Health Financing Collaborator Network*
Summary
Background Achieving universal health coverage (UHC) requires health financing systems that provide prepaid 
pooled resources for key health services without placing undue financial stress on households. Understanding 
current and future trajectories of health financing is vital for progress towards UHC. We used historical health 
financing data for 188 countries from 1995 to 2015 to estimate future scenarios of health spending and pooled health 
spending through to 2040. 
Methods We extracted historical data on gross domestic product (GDP) and health spending for 188 countries from 
1995 to 2015, and projected annual GDP, development assistance for health, and government, out-of-pocket, and 
prepaid private health spending from 2015 through to 2040 as a reference scenario. These estimates were generated 
using an ensemble of models that varied key demographic and socioeconomic determinants. We generated better 
and worse alternative future scenarios based on the global distribution of historic health spending growth rates. Last, 
we used stochastic frontier analysis to investigate the association between pooled health resources and UHC index, a 
measure of a country’s UHC service coverage. Finally, we estimated future UHC performance and the number of 
people covered under the three future scenarios.
Findings In the reference scenario, global health spending was projected to increase from US$10 trillion 
(95% uncertainty interval 10 trillion to 10 trillion) in 2015 to $20 trillion (18 trillion to 22 trillion) in 2040. Per capita 
health spending was projected to increase fastest in upper-middle-income countries, at 4·2% (3·4–5·1) per year, 
followed by lower-middle-income countries (4·0%, 3·6–4·5) and low-income countries (2·2%, 1·7–2·8). Despite 
global growth, per capita health spending was projected to range from only $40 (24–65) to $413 (263–668) in 2040 in 
low-income countries, and from $140 (90–200) to $1699 (711–3423) in lower-middle-income countries. Globally, the 
share of health spending covered by pooled resources would range widely, from 19·8% (10·3–38·6) in Nigeria to 
97·9% (96·4–98·5) in Seychelles. Historical performance on the UHC index was significantly associated with pooled 
resources per capita. Across the alternative scenarios, we estimate UHC reaching between 5·1 billion (4·9 billion to 
5·3 billion) and 5·6 billion (5·3 billion to 5·8 billion) lives in 2030.
Interpretation We chart future scenarios for health spending and its relationship with UHC. Ensuring that all 
countries have sustainable pooled health resources is crucial to the achievement of UHC.
Funding The Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Estimates of future global and national health spending 
are valuable inputs for health system planning and can 
guide progress towards achieving universal health 
coverage (UHC). UHC has emerged as both a global and 
national health priority, and progressive realisation of 
UHC is viewed as a critical path for improving health 
outcomes and achieving greater equity in health across 
all populations. Globally, the importance of UHC is 
highlighted by its codification in the Sustainable 
Development Goals (SDGs) in 2015, although its thematic 
origins come from the Alma Ata Declaration of 1978.1,2 
Nationally, the health benefits and protections against 
catastrophic health spending that result from UHC are 
highlighted by UHC exemplars such as Japan, Chile, 
and Thailand, and UHC initiatives or proposals are 
increasingly topping policy agendas.3–7 Numerous case 
studies have sought to identify key factors in achieving 
UHC and have posited several drivers, including sustained 
political will, clearly defined health service packages, and 
phased implementation to ensure that all populations are 
covered.8,9 However, across development and health-care 
settings, it is increasingly recognised that creating and 
maintaining robust health financing systems is equally 
important to achieving UHC.
Achieving UHC for all populations requires the 
harmonisation of political, social, economic, and health 
leadership, as well as mature health systems capable of 
ensuring efficiency and equity. Furthermore, health 
financing systems must be able to deliver a sufficient set 
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of pooled resources for health,10,11 which requires 
sustaining sufficient supplies of resources to finance 
key health services at the country level. Pooled resources 
consist of prepaid revenues through govern ment 
financing, social health insurance, private in surance, or 
development assistance for health (DAH), which help to 
mitigate individual-level financial risks across popu-
lations and thus fund care for more people. The 
cornerstones of UHC—providing access to essential 
health services for all populations and protection against 
catastrophic health spending—are best supported 
through the establishment of sufficient and stable 
supplies of pooled resources for health. Conversely, 
persistent challenges in the stability or sufficiency of 
pooled health resources, as well as reliance on out-of-
pocket spending, can significantly hinder whether and 
how UHC can be successfully implemented, scaled 
up, and maintained. Tracking country-level pooled 
resources for health and understanding how trends in 
the avail ability of resources can affect UHC performance 
are vital inputs into policy dialogues and budgeting 
processes related to UHC.
Little is known about how financial resources for health 
might catalyse or constrain potential future progress on 
UHC. Previous studies have explored how to translate 
health resources into achieving UHC by offering cost 
estimates for UHC attainment. Although such studies 
can be useful for initial planning purposes, they often fail 
to account for system inefficiencies and implemen-
tation challenges associated with programmatic scale-
up. Moreover, measures of health-service costs are 
fundamentally different from quantification of the 
amount of total health spending needed to implement 
and sustain national health systems. Other studies have 
tracked historical changes in total health spending and 
the associations between these changes and income, 
as well as retrospective relationships between public 
spending on health and UHC progress.11–15 However, such 
Research in context
Evidence before the study
Achieving universal health coverage (UHC)—ie, access to 
essential health services and financial risk protection—
is increasingly viewed as crucial to improving health outcomes. 
Despite the ascent of UHC in global and national policy 
agendas, little is known about how health financing might or 
might not constrain progressive realisation of this goal. 
Previous studies, including work by the Global Burden of 
Disease Financing Global Health Collaborator Network, have 
provided past estimates and predictions of total health 
spending and spending disaggregated by source 
(ie, government, out-of-pocket, and prepaid private spending 
and development assistance for health); however, these 
analyses have not directly examined how these financing trends 
might relate to UHC. At the country level, a key component of 
successful UHC programme design and sustainability is the 
existence of a sufficient, stable supply of pooled resources for 
health. The Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) 2016 produced projections of health service 
coverage through to 2030 on the basis of past trends for 
188 countries. Although an important first step, these 
estimates did not account for potential financing constraints. 
To better inform long-term investments for UHC initiatives and 
financing, it is crucial to understand how country-level pooled 
resources are related to gains in UHC performance.
Added value of this study
Drawing from past trends and relationships between key 
economic, demographic, and health financing indicators for 
188 countries from 1995 to 2015, we estimated three future 
scenarios for health spending through to 2040. These scenarios 
consisted of a reference scenario, as well as better and worse 
scenarios, which constituted the 85th and 15th percentiles of 
long-term global health spending growth rates, respectively. 
We then assessed the relationship between pooled health 
resources per capita and performance on the UHC index, 
a summary measure of UHC service coverage developed as part 
of the GBD 2016 study. We used the relationship between 
financing and UHC index to evaluate the frontier for UHC 
achievement on the basis of past levels of health spending. 
The frontier represents the modeled optimal UHC index for 
each amount of pooled health spending per capita. We then 
applied the relationships identified to the three future health 
spending scenarios to quantify the possible trajectories and the 
extent to which they catalysed (or constrained) future gains in 
UHC by country, income group, and GBD super-region.
Implications of all the available evidence
Although per capita health spending was projected to 
significantly increase worldwide, such gains were varied, and 
most increases in health spending and pooled health spending 
were concentrated among upper-middle-income and 
high-income countries rather than lower-middle-income and 
low-income countries. By 2040, country-specific pooled 
spending per capita was projected to range from 
$30 to $14 876, a magnitude of disparity that could hinder 
progress on UHC for many places most in need. We found that 
greater pooled health resources per capita were positively 
related to the UHC index performance and could be a part of 
substantial gains in UHC. With 2015 as the baseline, our better 
and worse health spending scenarios projected that 
0·8–1·3 billion additional lives could be covered with UHC 
service coverage by 2030 and 1·1–2·0 billion by 2040. These 
results not only emphasise the overall importance of sustained 
pooled resources for health, but also the potential to 
substantially accelerate global gains if the better financing 
scenarios can be actualised. Across the development spectrum, 
deliberate action focused on the expansion of pooled resources 
for health will be crucial to bringing the aspirations of UHC 
closer to reality for all populations.
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analyses do not shed light on what resources might be 
available in the future and how they can be leveraged to 
accelerate advances in UHC.
We used historical health financing data for 
188 countries from 1995 to 2015 to estimate future 
scenarios of health spending and pooled health spending 
through to 2040. Additionally, we assessed past relation-
ships between pooled health spending and perfor-
mance on a measure of UHC service coverage. Last, we 
quantified the magnitude by which changes in health 
financing, as projected into the future, could lead to 
changes in UHC by 2030 and 2040—key information for 
the development of long-term policy and strategy to 
achieve UHC.
Methods
Overview
We estimated national GDP, government spending, 
health spending, and performance on the UHC index for 
each year through to 2040 for 188 countries. Our estimates 
are based on past trends and relationships from economic, 
demographic, and health financing data over time. The 
methods used build and improve on the methods from 
our previous research.16,17 More detail on these methods 
and the data used in this analysis are provided later in 
this paper and in the appendix (pp 10–20). In brief, 
these methodological advances include the estimation of 
alternative (better and worse) future scenarios in addition 
to reference scenarios for each country; development of a 
structural framework to identify key covariates upon 
which to build our econometric models; and incorporation 
of several improvements to identify, rank, and pool the 
models that ultimately compose our final ensemble model 
and estimates of uncertainty.18 We then used these 
financing projections to estimate UHC index performance 
for each country-year through to 2040 using stochastic 
frontier analysis (SFA). All analyses were done with 
R Statistical Software and R-INLA, and visualisations were 
produced with ggplot2.19–23
Data
We extracted health spending data for 188 countries 
spanning 1995–2015 from the Institute for Health Metrics 
and Evaluation’s (IHME) Financing Global Health 
2017 database.24 These data build on data published in the 
WHO Global Health Expenditure Database, as well as 
additional global health financing data such as National 
Health Accounts and project-level DAH data from 
23 major channels of development assistance; additional 
details on how the Financing Global Health 2017 database 
was constructed are available elsewhere.24,25 These data 
track current health spending (ie, net of investment 
spending) and are composed of four mutually exclusive 
categories: government health spending from domestic 
sources, which includes general government and social 
health insurance; prepaid private health spending, 
which includes private insurance and non-governmental 
organisation spending; out-of-pocket health spending, 
which includes all spending at point of service and 
copayments; and DAH, defined as the financial and 
in-kind resources transferred from development agencies 
to low-income and middle-income countries with the 
primary purpose of maintaining or improving health.25
We calculated GDP and government spending data 
for 188 countries from 1970 to 2017 using methods that 
have been described elsewhere.26 GDP and all spending 
estimates were modelled and reported in 2017 purchasing 
power parity US$ adjusted for inflation.
We used the UHC index, which was developed as part 
of the Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) 2016.27 This index is a summary 
measure of health service coverage that is based on the 
coverage of nine interventions and risk-standardised 
rates of death from 32 causes amenable to health care. 
The nine interventions are primarily focused on 
infectious diseases and reproductive, maternal, and child 
health priority areas (ie, coverage of DPT3 vaccine, 
measles vaccine, polio vaccine, at least one antenatal 
visits, at least four antenatal visits, presence of a skilled-
birth attendant, in-facility birth, antiretroviral therapy, 
and met need for family planning with modern 
contraception methods). The 32 causes of death were 
components of the Healthcare Access and Quality (HAQ) 
index, which represents a wider range of key health 
conditions, including cancers, stroke, and diabetes;28 
although the UHC index draws from components of 
the HAQ Index, it is not exclusively composed of risk-
standardised rates of death from causes amenable to 
health care. In 2016, UHC index values ranged from 85·7 
(95% UI 82·0–89·3) in Switzerland to 26·9 (24·2–30·1) 
in Somalia. A full description of the UHC index 
components and its construction is available in the 
appendix (pp 21–24).27
Reference case for future health spending
We estimated the annual growth rate of GDP from 
2018 to 2040 using an ensemble modelling approach. 
Covariates for potential model inclusion were fraction of 
total population younger than 20 years and older than 
65 years (separately), average years of education, total 
fertility rate, and a convergence term, which is the 1-year 
lag of the non-differenced dependent variable. Inclusion 
of the convergence term allows for models in which 
countries spending more on health have slower spend-
ing growth rates. This models converging amounts of 
spending per capita. We also included four distinct 
weight schemes to weight recent years more heavily, as 
well as up to three degrees of autoregressive terms 
and up to three degrees of a moving average residual. 
The combination of covariates and alternative models 
specifications leads to 11 520 potential models. We 
selected 825 of 11 520 possible model specifications, after 
excluding models with non-significant independent 
variables (p value greater than 0·10), an estimated 
See Online for appendix
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coefficient on the convergence terms greater than zero, 
and predictions that fell outside the bounds of historical 
GDP growth from 1970 to 2017. More detail is provided 
in the appendix (p 15).
Out-of-pocket and prepaid private health spending, as 
well as total government spending were modelled as a 
share of GDP, whereas government health spending was 
modelled as a share of total government spending. We 
used the previously described ensemble modelling 
approach for each measure, and conducted this modelling 
in sequence, such that projected esti mates were used 
as covariates in subsequent models, as shown in the 
appendix (pp 10, 11).20,21
We used a three-step process to estimate the future 
DAH disbursed to low-income and middle-income 
countries. For sources of DAH that are countries or 
national treasuries, we modelled DAH as a share of the 
source’s government spending to make estimates of 
total DAH provided from 2018 to 2040. For sources 
without an associated GDP time series, such as 
corporate donations and private foundations, we 
estimated future DAH using autoregressive integrated 
moving average (ARIMA) models with no covariates. 
Second, we modelled DAH received for each recipient 
country, measured as a share of the total amount of 
DAH provided through 2040. Finally, we estimated the 
transition of countries from middle-income to high-
income status on the basis of GDP per capita. This 
transition occurs when GDP per capita surpasses 
$13 741 per capita, the point of high-income transition 
defined by the World Bank.29 To estimate total health 
spending for the reference scenario, we added DAH 
received by countries to country-level reference 
estimates for government, prepaid private, and out-of-
pocket health spending.
Alternative future health spending scenarios
In addition to generating a reference scenario for each 
country from 2016 to 2040, we estimated two sets 
of alternative health spending scenarios for total, govern-
ment, prepaid private, and out-of-pocket spending and 
DAH. These alternative scenarios, termed the better and 
worse scenarios are associated with greater and fewer 
resources being available for health, respectively, 
compared with the reference scenario. Although many 
high-income countries might prefer to limit rather than 
expand health spending, from the vantage point of the 
health sector exclusively, having more resources for 
health is generally better. To inform these alternative 
scenarios, we first regressed 20 year growth rate of total 
health spending per capita from 1995 to 2015 on the 
convergence term. We then computed better and worse 
growth rates for each country by adding the country-
specific fitted value and 85th or 15th percentiles of the 
estimated residual of the long-term growth rates, which 
resulted in better and worse future scenarios for total 
health spending per capita, by country, from 2016 to 2040. 
In cases where better or worse scenarios were higher or 
lower than the reference projections, we adjusted the 
respective scenarios to overlap with the reference case. 
We completed this process for government health, pre-
paid private, and out-of-pocket spending and DAH and 
scaled these estimates proportionally to the better and 
worse total health spending scenarios.
Relationship between health spending and UHC index 
performance
To measure the relationship between health spending 
and UHC index performance, we used SFA to regress 
annual country-specific UHC index estimates on per 
capita pooled resources for health (ie, the sum of 
government health spending, prepaid private spending, 
and DAH). We selected SFA over other methods such as 
data envelop ment analysis because SFA allowed us to 
incorporate measurement error and to draw from a 
wide range of peer countries to set the frontier—ie, the 
modelled optimal UHC index for each amount of pooled 
health spending per capita. The gap between the frontier 
and observed spending represents the sum of 
measurement error and unobserved factors related to 
the translation of health spending into gains in UHC.15 
These factors, which we refer to collectively as 
inefficiency, reflect a range of influences, within and 
outside the health sector, that might ultimately prevent 
a country from reaching the UHC index frontier; such 
factors include social, political, demographic, and 
economic trends, as well as those within the health 
sector that can affect efficiency, such as governance and 
corruption. To model these unobserved factors, we 
assumed a one-sided half-normal distribution of 
residuals. 
Using SFA, we estimated potential future performance 
on the UHC index based on the three pooled health 
spending scenarios (reference, better, and worse). We 
measured the gap between the frontier and observed 
UHC index at the country level by use of time series 
regression. Further details are provided in the appendix 
(pp 22–24).
The UHC index provides a good approximation of the 
average coverage of essential health services across a 
wide range of priority health areas. To estimate the 
number of people covered by UHC health services, we 
assumed the UHC index to be a coverage measure and 
multiplied the UHC index by each location-year-specific 
population. This assumption allows the aggregation 
across individuals estimated to be covered with a subset 
of the high-quality services.
We categorised potential drivers of change in UHC 
index performance into two distinct components, using 
the decomposition method described by Das Gupta: the 
change in UHC index performance associated with 
changes in pooled total health spending per capita and 
the change in performance associated with changing 
efficiency.30
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Aggregation across income groups and regions
We report health spending and UHC index performance 
for each country, World Bank 2017 income group, and 
GBD super-region.29,31 We aggregated spending per 
capita or per GDP by calculating spending for the group 
relative to the total population or GDP; subsequently, 
these measures reflect the group or region as a whole 
instead of the average of countries comprising the 
given group. We used population-weighted means to 
measure the UHC index by income group or GBD 
super-region. We report all estimates up to 2040, and 
highlight some of the projected figures for 2030, given 
its significance as the target year for achieving SDGs. 
The full results for all time periods are presented in the 
appendix (pp 65–75).
Uncertainty
We propagated uncertainty throughout our analysis. 
For reference scenarios, we used a four-part process to 
capture data, model, and parameter uncertainties. 
First, to propagate data uncertainty, we randomly selected 
different draws for historical data and covariates. 
Second, to propagate model uncertainty, we used the 
ensemble modelling framework. Third, to propagate 
parameter uncertainty, we took a random sample from 
the posterior distributions of each model specification to 
create at least 1000 draws. Fourth, we added empirical 
noise to our linear projections using a first-order random 
walk. The variance of the random walk was determined 
by estimated residuals from the out-of-sample validation. 
Countries where sub-models did not fit the observed 
data well have the largest uncertainty. For alternative 
scenarios, the uncertainty from the mean of reference 
scenarios was added to the better and worse scenarios. 
We completed the frontier analyses and future UHC 
estimation using each of the estimated draws. Each 
estimate reported in this text is a mean of these 
1000 draws, and the uncertainty interval (UI) was 
constructed by extracting the range between the 
2·5th and 97·5th percentile of the 1000 draws.
Role of the funding source
The funder of this study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and the corresponding author had final 
responsibility for the decision to submit for publication.
Results
In 2015, $10 trillion (95% UI 10 trillion to 10 trillion) was 
spent on health globally, and total health spending was 
projected to reach $15 trillion (14 trillion to 16 trillion) in 
2030 and $20 trillion (18 trillion to 22 trillion) in 2040. In 
2040, health spending per capita is expected to be 45·9 
(37·1–54·6) times larger in high-income countries than in 
countries that are considered low-income currently. Across 
the four income groups, we estimated that health spending 
per capita in 2040 would be $8666 (7430–9657) for high-
income countries, $2670 (2217–3302) for upper-middle-
income countries, $714 (638–801) for lower-middle-income 
countries, and $190 (166–219) for low-income countries 
(table 1). Within the income groups, expected spending on 
health also varied dramatically, with per capita health 
spending projected to range from only $40 (24–65) to $413 
(263–668) in 2040 in low-income countries, and from $140 
(90–200) to $1699 (711–3423) in lower-middle-income 
countries. Per-capita spending was projected to increase in 
174 of 188 countries, with the largest increases in spending 
in upper-middle-income-countries (4·2%, 3·4–5·1).
Figure 1 shows the estimated growth rates across time 
and spending category globally, for each income group and 
GBD super-region. Globally, growth rates for total 
spending were expected to be relatively constant across the 
next 25 years, with an average of 3·0% (95% UI 2·6–3·4) 
over time. The largest growth rates were for out-of-pocket 
spending, followed by government health spending and 
DAH. Growth rates for per-capita spending, however, were 
expected to decrease over time in all GBD super-regions 
and income groups except low-income. Across income 
groups, the highest average annual growth rates for total 
spending over time were estimated to occur in low-income 
countries (5·0%, 4·5–5·7) and lower-middle-income 
countries (4·9%, 4·5–5·4); the largest annualised growth 
rates were for prepaid private spending and government 
health spending. Despite having the largest health 
spending growth rate, health spending per-capita growth 
in low-income countries was projected to remain low 
(table 1). The region of southeast Asia, east Asia, and 
Oceania was projected to have the highest average annual 
growth over time (5·6%, 4·5–6·8), followed by south Asia 
(5·3%, 4·7–6·1), although growth declined across time. 
The highest growth rates were for prepaid private spending 
in south Asia and government health spending in 
southeast Asia, east Asia, and Oceania. The GBD high-
income region was estimated to have the lowest total 
spending growth (1·9%, 1·3–2·4).
Focusing on the growth of per-capita pooled spend-
ing (ie, government health spending, prepaid private 
spending, and DAH) we estimated a projected global 
growth rate of 2·0% (95% UI 0·5–3·4) per year for 
2015–40. In contrast, out-of-pocket spending was projected 
to increase at an annualised rate of 2·6% (2·3–3·0) 
from 2015 to 2040 (table 1). Upper-middle-income 
countries had the largest rate of growth in pooled spending 
per-capita, at 4·3% per year (2·4–6·1), whereas lower-
middle-income countries were also pro jected to have 
substantial growth in pooled spending, at 3·9% per year 
(2·2–5·6). By 2040, it was estimated that pooled resources 
in these countries would reach only 42·1% (37·0–47·4) 
of total health spending and remain at $300 per capita 
(261–345; table 2). Under the reference scenario, high-
income countries had the largest projected pooled 
health spending per capita ($7508, 5192–9814) in 2040. 
Conversely, the lowest projections for pooled health 
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spending per capita in 2040 were in sub-Saharan Africa 
($175, 152–207), and south Asia ($273, 211–342).
Globally, the estimated growth rate for total health 
spending under the better future scenario was 4·2% per 
year (3·8–4·5) through to 2040; however, even within this 
group of better scenarios, growth rates across countries 
ranged from 2·1% (0·4–4·5) in Liberia to 6·3% (5·0–7·8) 
in China. Growth rates for individual countries are 
available online. By 2040, the difference between the 
reference and better future scenarios for total health 
spending per capita was $1386 (1279–1477), with the better 
scenario being 59·9% (55·2–63·7) higher than the 
reference in 2040. Relative to the reference scenario, 
sub-Saharan Africa had the largest potential percentage 
gains under the better scenario by 2040. Furthermore, the 
better future scenario showed growth potential for pooled 
financing, with an annualised global growth rate of 
4·0% (2·7–5·4). The better scenario would increase pooled 
health spending by 62·8% (60·3–69·0) compared with the 
reference by 2040. Across countries, the better future 
scenario for pooled resource growth ranged from 
1·5% (–0·9 to 4·6) in Liberia to 6·7% (4·8 to 8·5) in China, 
reflecting important potential for gains.
For the worse health spending future scenario, the 
global growth rate was –0·3% (–0·7 to 0·0) through 
to 2040. The gap in total health spending per capita was 
$1085 (959 to 1234) between the reference and worse 
future scenarios, and spending was 46·8% (44·9 to 49·0) 
lower in the worse scenario than in the reference scenario 
in 2040. Under the worse scenario, pooled resources for 
health were projected to decrease at an annualised rate of 
0·3% (–1·5 to 0·8).
Drawing from the empirical relationship between 
pooled resources per capita and the UHC index, we 
generated a UHC frontier, which highlights how 
financing can constrain progress in achieving UHC, as 
well as the gaps between potential and observed UHC 
(figure 2). The distance between observed performance 
Figure 1: Annualised growth in total health spending per capita
Per capita spending is measured in 2017 purchasing-power parity-adjusted dollars adjusted for inflation. Income groups are based on 2017 World Bank income 
groups held constant across time. Black lines represent uncertainty intervals. Projections are based on the reference scenario. Black diamonds show expected 
population growth rates. GBD=Global Burden of Disease.
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on a country’s UHC index and the frontier values 
estimated on the basis of the pooled resources per capita 
can reflect current challenges in translating national 
health resource into the maximum expected UHC index. 
The figure shows the large variations in the level of 
system inefficiency that hinders countries from achieving 
the optimal level of UHC. Despite this variation, the 
upward and significant (p<0·0001) slope of the UHC 
frontier shows a positive relationship between pooled 
resources for health and the UHC index: a 10% increase 
of pooled resources per capita was associated with a 
1·4% (1·4–1·5) increase in the UHC index. Some 
countries, such as China and India, increased pooled 
spending per capita by more than 265% between 
1995 and 2015 and had increases in UHC index of 
approximately 40%, suggesting that increases in spending 
can lead to substantial progress towards UHC.
Drawing from the UHC index frontier and the future 
scenarios for pooled health resource spending, we 
projected that, globally, the UHC index would increase to 
64·8 (95% UI 61·8–67·0) in 2030, a 9·4% (4·6–14·2) rise 
from 2015 (figure 3), and to 67 (63–71) in 2040, a 13·7% 
(6·5–21·0) rise from 2015. Between 2015 and 2030 (the 
timespan for the SDGs), lower-middle-income countries 
saw the largest gains on the UHC index relative to their 
starting point, rising 15·6% (10·6–20·8) between 
2015 and 2030. By contrast, high-income countries had 
the smallest increase, rising by 4·0% (0·9–6·7) between 
2015 and 2030. During this same time, UHC index 
increased by 14·0% (7·0–21·7) in low-income countries 
and 10·4% (5·2–15·7) in upper-middle-income countries. 
In all four income groups, these gains are expected to 
continue through 2040. Sensitivity analyses reported in 
the appendix highlight that these results are robust to 
alternative modelling assumptions. 
Figure 4 shows the drivers of increases in UHC, 
decomposing the increase from 2015 to 2030 and from 
2030 to 2040 into two distinct drivers—changes in the 
UHC index associated with changes in pooled health 
resources per capita and changes in the UHC index 
associated with changes in health system inefficiency 
and contextual factors. In most lower-middle-income, 
upper-middle-income, and high-income countries, 
increases in pooled spending per capita were predicted to 
be the primary drivers of the largest increases in UHC 
performance. Between 2015 and 2030, the proportion of 
the improvement in UHC index attributable to changes 
in pooled spending was 58·1% (40·9–68·7) in lower-
middle-income countries, 98·0% (96·8–98·6) in upper-
middle-income countries, and 74·2% (23·3–87·3) in 
high-income countries. Conversely, the propor tion of 
improvement attributable to changes in system efficiency 
and contextual factors was 41·9% (31·3–59·1) in lower-
middle-income countries, 2·0% (1·4–3·2) in upper-
middle-income countries, and 25·8% (12·7–76·7) in 
high-income count ries. For low-income countries and 
sub-Saharan Africa, we estimated that gains in efficiency 
and improvements in the contextual factors would 
lead to larger increases in UHC index (67·8% 
[43·5–97·0] in low-income countries and 66·7% 
[39·3–97·4] in sub-Saharan Africa, respectively). In the 
longer term (2030–40), however, projected increases in 
the amount of pooled resources per capita would have a 
larger impact in the progress towards UHC (55·7% 
[16·0–73·0] in low-income countries and 93·5% 
(90·9–95·4) in high-income countries).
Figure 5 shows the change in the number of lives 
covered globally between 2015 and under the reference 
and better scenarios in 2030, as well as the distribution of 
the UHC index across countries. In 2015, we estimated 
that 4·3 billion (95% UI 4·2 billion to 4·4 billion) lives 
were covered under UHC, with the UHC index ranging 
from 26·5 (23·8–29·6) in Somalia to 85·3 (81·8–88·5) in 
Switzerland (table 2) across countries and half of the 
global population living under health systems with a 
UHC index less than 60. On the basis of the projected 
progress on the UHC index between 2015 and 2030, we 
estimated that an additional 1·1 billion (0·8 billion to 
1·3 billion) people would be covered in 2030 under the 
reference scenario, and a further 196 million (186 million 
to 205 million) lives would be covered under the better 
scenario. The most pronounced projected gains in 
lives covered be tween 2015 and 2030 (shifts upward on 
figure 5) were for low-income countries (205·6 million 
[176·2 million to 236·6 million]; increase of 
75·2% [64·4–87·0]), sub-Saharan Africa (303·9 million 
[252·7 million to 357·2 million], increase of 70·6% 
[58·9–83·6]), and South Asia (274·2 million [237·0 million 
to 304·5 million], increase of 33·5% [29·0–38·2]; table 2). 
Across income groups, there was a strong relationship 
Figure 2: Universal health coverage financing frontier
Pooled health spending per capita for 2015 is measured in 2017 purchasing-power parity-adjusted dollars adjusted 
for inflation. The red line represents the fitted frontier value of the universal health coverage index fitted using data 
from 1995 through 2015. Each dot represents a country colour-coded by Global Burden of Disease super-region. 
GBD=Global Burden of Disease.
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between national income and the proportion of the 
population covered. By 2030, UHC was projected to cover 
1·0 billion (0·9 billion to 1·0 billion) people in high-
income countries (79·9% [77·3–81·8] of the population), 
whereas coverage was projected to be 72·4% (68·9–75·4) 
in upper-middle-income countries, 58·2% (55·3–60·2) in 
lower-middle-income countries, and 48·7% (45·6–51·9) 
in low-income countries. In addition, our analysis shows 
a projected difference of 870·5 million (790·4 million to 
940·8 million) people being covered between the better 
and worse scenarios, stressing the need to ensure 
sufficient health financing for UHC in the SDG era.
Discussion
Our projections highlight the large differences in expected 
future health spending and pooled health spending per 
capita across the globe, with high-income countries 
projected to spend 45·9 times (95% UI 37·1–54·6) more 
on total health expenditure per capita than low-income 
countries in 2040. Moreover, our reference scenario 
suggests relatively poor growth in pooled health spending 
for some countries that are already spending very little on 
health, including Angola, Benin, Chad, Guinea-Bissau, 
Nigeria, and Congo (Brazzaville). Our analysis, which 
quantifies the relationship between pooled resources for 
health per capita and potential performance in terms of 
UHC service coverage, showed a strong relationship 
between increased pooled resources and improved UHC 
performance. The gap between observed and potential 
UHC index performance given a country’s pooled 
resources per capita varied considerably across countries, 
showing opportunity to better leverage these resources for 
UHC gains. Better and worse scenarios for health 
spending shed light on how trajectories in total health 
spending and pooled resources could enable accelerated 
gains in UHC or constrain progress if advances in health 
resources for UHC are not realised. 
There is increasing global consensus on UHC and its 
ability to improve population health outcomes in an 
equitable, sustainable manner. Yet far less agreement 
exists in terms of how to translate UHC ambitions into 
reality, both in terms of universal service coverage 
and financial risk protection for all populations. Most 
recommended strategies focus on particular aspects 
of reaching UHC, such as strengthening human 
resources for health, improving the quality or efficiency 
of care provided, and updating the package of health 
services covered by insurance schemes.32,33 However, 
fundamental to the success of these strategies, as well as 
overall UHC programme implementation and long-term 
Figure 3: Universal health coverage in 2030
Projections are based on the reference scenario. Grey signifies countries without estimates. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and 
Tobago. Isl=Islands. FSM=Federated States of Micronesia. TLS=Timor-Leste. 
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sustain ability, are sufficient and stable health financing 
systems. Understanding the levels, trends, and future 
scenarios for country-level health financing—and how 
these trajectories relate to potential advances in UHC—
is crucial to informing policy and investment decisions 
regarding UHC.
Globally, we projected that the largest growth in total 
health spending would be in government spending from 
2015 to 2040, although growth rates were highest for 
out-of-pocket health spending. Notably, the magnitude of 
this growth varied by and within income groups and 
GBD super-regions. We found that countries with 
substantial projected growth in pooled spending also had 
large projected gains in performance on the UHC index, 
which aligns with previous research on how pooled 
resources for health are positively related to UHC. By 
contrast, reliance on out-of-pocket spending, which was 
also estimated to grow, has been shown to deter care and 
lead to catastrophic health spending or impoverishment.17,34
While not causal, the strong, positive relationship 
between pooled spending per capita and UHC index aligns 
with previous work that has described the relationships 
between higher public spending on improved service 
coverage and health outcomes.15,35,36 Economic theory 
further posits that the pooling of financial resources 
spreads financial risk across the population, and because 
individuals are protected from carrying the full burden of 
paying for their own health services, they are more likely to 
access and receive care.37 Globally, we found that along the 
frontier, a 10% increase in pooled health spending 
per capita from 2015 to 2030 was associated with a 
1·4% (1·4–1·5) increase in performance on the UHC 
index. While this observation is encouraging, many 
countries remain some distance from the frontier, 
suggesting that gains in UHC could also be made by 
improving health system efficiency. Some countries, 
including Sri Lanka and South Korea, had projections 
exceeding this pace for both pooled heath spending and 
UHC performance, findings supported by past work 
documenting these countries’ exceptional progress on 
UHC relative to their development status. It is important 
to recognise that increasing health spending is neither a 
necessary nor sufficient condition for improving UHC; 
the USA provides a counterexample, wherein very high 
health spending has not translated into high access to 
quality care for all populations. Rather, ensuring a supply 
of additional pooled resources for UHC, alongside other 
important sociopolitical factors and policy levers, is likely to 
provide a strong foundation for equity-focused, sustainable 
UHC programmes.
The intersection of pooled health spending and 
financial risk protection—the other key component of 
achieving UHC in the SDG area—has important 
programmatic and policy ramifications, particularly in 
terms of sustainably funding UHC initiatives. Protection 
against catastrophic health spending is generally offered 
through nationally funded insurance schemes or 
programmes that involve a mixture of privately and 
publicly funded insurance.38 Subsequently, the present 
study’s quantification of the relationships between health 
spending and UHC service coverage performance might 
represent an overall underestimate of the pooled funds 
needed to achieve UHC more broadly. This might be 
particularly relevant in countries where the composition 
of total health spending has been historically more heavily 
skewed toward out-of-pocket or prepaid private health 
spending at the population level. Although valuable 
improvements in the measurement of catas trophic health 
spending have been made, no full time series currently 
exists for household catastrophic health spending 
across countries.39,40 This data scarcity poses substantial 
challenges for the evaluation of potential shifts in res-
ponse to policy implementation or the effects of pooled 
resources for health, although valuable improvements in 
the measurement of catastrophic health spending have 
been made. A critical area of future work entails not only 
Figure 4: Increase in universal health coverage index from 2015 to 2030, by driver
Income groups are based on 2017 World Bank income groups held constant across time. Universal health coverage 
index is the population weighted mean for each income group and Global Burden of Disease super-region. Black lines 
show the year-specific measure of the universal health coverage index. The bars connecting the black lines show the 
drivers of the universal health coverage index increases . Projections are based on the reference scenario. GBD=Global 
Burden of Disease.
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generating estimates of financial risk protection for all 
countries and over time, but also evaluating the 
relationships between pooled health spending and the 
distribution of catastrophic health spending.
Generating future scenarios for pooled resources and 
potential UHC performance through 2040 has many 
applications, particularly in terms of budgetary planning 
and consideration of the impact of different investments. 
Our selection of three scenarios—reference, better, and 
worse—offers empirically derived guidance on what the 
world could achieve within realistic, albeit ambitious, 
parameters. Our better and worse scenarios were set to 
reflect the realistic extremes achieved historically by 
some countries, rather than hypothetical rates of growth 
or other arbitrary thresholds. We ground these scenario-
based projections in what has been possible in the past, 
therefore offering a platform on which bold, and 
pragmatic, policy options can be evaluated.
This research also helps highlight the role health 
system efficiency can play in helping countries to 
progress towards UHC. We found that, in many 
countries, improvements in system efficiency could lead 
to similar or even larger UHC gains than solely 
increasing the amount of pooled resources. Although we 
found large variations in efficiency levels across 
countries, we cannot establish the causes of inefficiency, 
which might include corruption, low health worker 
productivity, excess administrative costs, spending on 
unnecessary care, or high prices, among others. Future 
work should consider how to quantify the drivers of 
system inefficiencies, as well as options for improving 
efficiency without jeopardising the quality of UHC.
More broadly, pathways to achieving UHC are complex 
and can come in various forms. Whether a country is 
successful in mobilising additional resources for UHC or 
improving system efficiency depends on not only technical 
knowledge, but also long-term, pragmatic political 
strategies that account for local political and historical 
legacies.41 How the benefits of UHC are distributed across 
different subgroups in a country needs to be actively 
discussed to ensure equity. Vulnerable populations, such 
as the poor, informal sector workers, and those living in 
rural areas, might be left without access to health coverage 
unless deliberate efforts are made to reach them. 
The allocation of the national health budgets towards 
UHC also needs to be balanced with spending on other 
crucial health areas, including health emergency 
preparedness, health promotion, and capital investments 
such as hospitals.42 Furthermore, in the absence of good 
governance and leadership at the national and local levels, 
any efforts towards and gains in UHC could be in vain. 
Such factors, as well as forces that primarily exist outside 
of the health sector (ie, physical infrastructure, education 
systems), have the potential to substantially accelerate or 
constrain a country’s progress toward UHC.
Estimating levels of future spending and how spending 
might affect UHC is intrinsically uncertain, given that 
spending patterns and health financing systems evolve 
over time and are shaped by many factors. These include 
national and international policymaking, shifts in the 
supply and demand of health services, economic 
development, changes in political regimes and policy 
directions, and economic, social, political, and abrupt 
events such as civil strife, natural disasters, and emergent 
epidemics. In the absence of systematic and credible 
projections of all of these factors, we rely on past global 
and country-specific spending trends and the relationships 
between these variables and underlying economic 
development, government spending, and demographic 
measures. To capture the uncertainty of these relationships 
in our future scenarios, we have sought to propagate 
uncertainty from a range of sources, including data, 
model, and parameter uncertainty. As advances are made 
to quantify projections of a wider range of factors related 
to UHC, we aim to incorporate them into our models and 
increasingly narrow our estimates of uncertainty.
Our study has some limitations. First, precise data on 
different types of health financing were not readily 
available across countries and over time. This is particularly 
challenging for out-of-pocket and prepaid private spending, 
given that many countries do not have robust information 
systems on such data and or because informal payments 
constitute a large share of health spending. For this study, 
we relied on data from the Institute for Health Metrics and 
Evaluation’s Financing Global Health database, estimates 
a complete dataset across time, and quantifies uncertainty.25 
Second, projected levels and types of health spending 
in 2040 were based on relationships observed from 
1995 to 2015. These projections reflect trends in country 
development and demographic changes, but cannot 
capture the full range of unobserved historical policy or 
Figure 5: Lives covered, 2015, and under the 2030 reference and 2030 better scenarios
On the horizontal axis, the global population is ordered by each country’s UHC index rank. Similar to a 
concentration curve, each shift in the graph represents a country, with longer lines representing more populous 
countries. The area under the curve represents the share of the global population covered by UHC services. 
UHC=universal health coverage.
0 25 50 75 100
0
25
50
75
100
Un
iv
er
sa
l h
ea
lth
 co
ve
ra
ge
 in
de
x 
Cumulative proportion of global population (%)
2030 better scenario:
196 (186–205) million 
additional lives covered
2030 reference scenario:
1065 (828–1286) million 
additional lives covered
2015: 4325 (4250–4390) 
million lives covered
Articles
www.thelancet.com   Vol 391   May 5, 2018 1795
environmental changes. Furthermore, these projections 
do not account for unknown future impacts of changes in 
international and national policy, macroeconomic 
development, new technologies, emergent epidemics, and 
natural disasters. Third, alternative frontier methods, such 
as data envelopment analysis, could have been used 
instead of SFA. However, our sensitivity analyses 
(appendix) showed that our overall results were robust to 
the choice of method. Fourth, the positive association 
between the share of pooled resources and UHC 
performance does not represent causality. More research is 
needed to explore the other possible mechanisms driving 
this relationship. Fifth, our measure of UHC focused on 
performance in terms of service coverage and health 
outcomes rather than both coverage and financial risk 
protection. Although we expect that protection from 
catastrophic health expenditure is well correlated with 
both pooled resources per capita and our measure of UHC, 
our current results do not capture the effects of financial 
risk protection on UHC performance and how pooled 
resources might support this aspect of UHC. Similarly, the 
current measure of UHC approximates personal health-
care access and quality, but our study cannot estimate the 
direct effect of pooled resources on quality of care. Future 
work to establish a cohesive metric of overall UHC, a 
measure of service coverage, quality of care, and financial 
risk protection, will support improved assessments of the 
funding required to reach and maintain high-quality UHC 
for each country over time.43 Sixth, the DAH dataset 
currently only includes financial flows from high-income 
countries to lower income countries. It does not capture 
the growing contributions and development assistance 
made by low-income and middle-income countries. 
Finally, we posit that, although more health spending per 
capita is better for the health system, there are many 
examples showing that greater spending does not always 
lead to better health outcomes. Equitable spending in 
allied sectors such as education and social protection has 
also been shown to affect health but was not considered in 
this study.44
Achieving UHC has great potential for improving 
population health outcomes and narrowing health 
inequalities. Ensuring that all countries across the 
development spectrum have a stable and sufficient supply 
of pooled resources for health is likely to help bridge 
current gaps in UHC performance. Our future health 
spending scenarios show the potential for spending to 
catalyse—or constrain—progress in UHC performance, 
particularly given the relationship between pooled 
resources per capita and levels achieved on the UHC 
index. These results are crucial for long-term resource 
planning and to address financing gaps: vital steps along 
the path to bringing UHC within reach of all populations.
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